Cellectis reports Phase 1 data for leukemia therapy lasme-cel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/7/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
October 16, 2025 3:19 PM UTCÂ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9)
Safety:Â in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 IEC-HS which resolved)
Durability:Â in patients who achieved MRD-negative CR/CRi, median OS was 14.8 months
In the target Phase 2 population, CR/CRi rate of 56% with ~80% of patients achieving MRD-negative status
In the target Phase 2 population, 100% patients became transplant eligible with 78% proceeding to transplant
... More